Alirocumab as Add-on To Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial -

Alirocumab as Add-on To Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Information type: Randomised controlled trials
Source: Journal of Clinical Endocrinology and Metabolism
Specialities: Cardiovascular system disorders
Summary
RCT (n=355) found that adding alirocumab, a monoclonal antibody to PCSK9, to atorvastatin provided greater LDL-C reductions vs adding ezetimibe, doubling atorvastatin dose, or switching to rosuvastatin (p<0.001 vs all comparators), and enabled greater LDL-C goal achievement.
UKMi comment
A marketing authorisation application has been submitted to the EMA for alirocumab (Praluent); if approved, it is expected to be launched in the UK in the first quarter of 2016.
Related links: